1690.1 – Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell to treat refractory or relapsed multiple myeloma

Highly specialised therapy – National Health Reform Agreement.

Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen receptor T (CAR-T) cell therapy for treatment of patients with multiple myeloma (MM) who are refractory or have failed more than three lines of prior therapy. The therapy involves taking the patient’s own cells from peripheral blood, enriching them for T-cells (a type of white blood cell that is an essential part of the immune system) and genetically modifying them before infusing them back into the patient to treat the MM.

Type: Therapeutic technology

Multiple Myeloma (MM) is a cancer affecting a type of white blood cell, known as a plasma cell. Plasma cells are found in the bone marrow and make up a part of the immune system. When cancerous, they accumulate to a point where there is not enough space left for normal, healthy blood cells to be produced. MM can cause bone disease, kidney problems, anaemia, increased risk of infection and blood-clotting.

• PASC consultation: Expedited – Bypassing PASC
• MSAC consultation: Closed

• PASC meeting: Expedited – Bypassing PASC
• ESC meeting: 5–6 October 2023
• MSAC meeting: 
  • 23–24 November 2023
  • 4–5 April 2024